Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

9.60
-0.5200-5.14%
Post-market: 9.49-0.1100-1.15%19:36 EDT
Volume:2.08M
Turnover:20.00M
Market Cap:1.72B
PE:-5.96
High:10.12
Open:10.00
Low:9.37
Close:10.12
52wk High:11.49
52wk Low:1.78
Shares:178.73M
Float Shares:97.65M
Volume Ratio:0.77
T/O Rate:2.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6113
EPS(LYR):-1.6113
ROE:-41.12%
ROA:-25.35%
PB:3.03
PE(LYR):-5.96

Loading ...

Relay Therapeutics reports Q4 EPS (32c), consensus (39c)

TIPRANKS
·
Feb 27

Earnings Flash (RLAY) Relay Therapeutics Posts Q4 Loss Per Share $0.32, vs. FactSet Est of $0.40 Loss

MT Newswires Live
·
Feb 27

Relay Therapeutics beats Q4 revenue expectations

Reuters
·
Feb 27

BRIEF-Relay Therapeutics Q4 Net Income USD -54.889 Million Vs. IBES Estimate USD -68.1 Million

Reuters
·
Feb 27

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

GlobeNewswire
·
Feb 27

Relay Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
Feb 25

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

GlobeNewswire
·
Feb 24

Relay Therapeutics Inc. to Report Fourth-Quarter and Full-Year Financial Results

Reuters
·
Feb 20

Why Relay Therapeutics (RLAY) Is Up 9.4% After FDA Breakthrough Tag For Breast Cancer Combo

Simply Wall St.
·
Feb 09

BRIEF-Relay Therapeutics Announces Zovegalisib Granted Therapy Designation By FDA For Pik3ca-Mutant

Reuters
·
Feb 03

Relay Therapeutics announces U.S. FDA granted BTD to zovegalisib

TIPRANKS
·
Feb 03

Relay Therapeutics Wins FDA Breakthrough Therapy Designation for Zovegalisib in Advanced Breast Cancer

Reuters
·
Feb 03

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for Pik3CA-Mutant, Hr+/Her2- Advanced Breast Cancer

THOMSON REUTERS
·
Feb 03

What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders

Simply Wall St.
·
Feb 02

Top Relay Therapeutics Insiders Quietly Cash Out in Coordinated Stock Moves

TIPRANKS
·
Jan 30

Relay Therapeutics : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Jan 26

Relay Therapeutics Raised to Outperform From Perform by Oppenheimer

Dow Jones
·
Jan 26

Oppenheimer Upgrades Relay Therapeutics to Outperform From Market Perform, Price Target is $14

MT Newswires Live
·
Jan 26

Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data

Simply Wall St.
·
Dec 26, 2025

ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn

Reuters
·
Dec 17, 2025